<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34218222</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1423-0208</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><Issue>5</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Neuroepidemiology</Title><ISOAbbreviation>Neuroepidemiology</ISOAbbreviation></Journal><ArticleTitle>Reproductive History and Age of Onset for Women Diagnosed with Amyotrophic Lateral Sclerosis: Data from the National ALS Registry: 2010-2018.</ArticleTitle><Pagination><StartPage>416</StartPage><EndPage>424</EndPage><MedlinePgn>416-424</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000516344</ELocationID><Abstract><AbstractText Label="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a neurological disease of largely unknown etiology with no cure. The National ALS Registry is a voluntary online system that collects demographic and reproductive history (females only) data from patients with ALS. We will examine the association between demographic and reproductive history among female patients aged &gt;18 years and various ages of onset for ALS.</AbstractText><AbstractText Label="METHODS">Data from a cross-sectional study were collected and examined for 1,018 female ALS patients. Patient characteristics examined were demographics including race, BMI, and familial history of ALS. Among patients, information on reproductive history, including age at menopause, ever pregnant, and age at first pregnancy was collected. Unadjusted and adjusted logistic regression models were used to estimate OR and 95% CI in this study.</AbstractText><AbstractText Label="RESULTS">Women were more likely to be diagnosed with ALS before age 60 if they were nonwhite (p = 0.015), had attended college (p = 0.0012), had a normal BMI at age 40 (p &lt; 0.0001), completed menopause before age 50 (p &lt; 0.0001), and had never been pregnant (p = 0.046) in the univariate analysis. Women diagnosed with ALS before age 60 were also more likely to have limb site of onset (p &lt; 0.0001). In the multivariate analysis, those who completed menopause before age 50 were more likely to be diagnosed with ALS before age 60 (OR = 1.8, 95% CI: 1.4-2.3) compared with women who completed menopause at or after age 50, after controlling for race, ever pregnant, age at first pregnancy, family history of ALS, education status, smoking history, and BMI at age 40. For women who were diagnosed with ALS before age 50, the odds of them entering menopause before age 50 climb to 48.7 (95% CI: 11.8, 200.9). The mean age of ALS diagnosis for women who completed menopause before age 50 was 58 years and 64 years for women who entered menopause after age 50 (p &lt; 0.0001).</AbstractText><AbstractText Label="CONCLUSION">Women who reported completing menopause before age 50 were significantly more likely to be diagnosed with ALS before age 60 compared with those who reported entering menopause after age 50. More research is needed to determine the relationship between female reproductive history, especially regarding endogenous estrogen exposure and early-onset ALS.</AbstractText><CopyrightInformation>&#xa9; 2021 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Ted</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pioro</LastName><ForeName>Erik P</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Section of ALS and Related Disorders, The Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry/Centers for Disease Control and Prevention, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuroepidemiology</MedlineTA><NlmUniqueID>8218700</NlmUniqueID><ISSNLinking>0251-5350</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017584" MajorTopicYN="N">Reproductive History</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Females</Keyword><Keyword MajorTopicYN="N">Menopause</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">Reproductive history</Keyword></KeywordList><CoiStatement>Competing interests: The CDC/ATSDR authors have no declarations of interest. Dr. Pioro has no declarations of interest linked to the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>4</Day><Hour>21</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34218222</ArticleId><ArticleId IdType="mid">NIHMS1745639</ArticleId><ArticleId IdType="pmc">PMC8506649</ArticleId><ArticleId IdType="doi">10.1159/000516344</ArticleId><ArticleId IdType="pii">000516344</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitsumoto H, Pioro EP., Amyotrophic lateral sclerosis., in F.A. Davis Company. 1998.</Citation></Reference><Reference><Citation>Mehta P, et al., Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep, 2018. 67(46): p. 1285&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner L, et al., State and metropolitan area-based amyotrophic lateral sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener, 2015. 17(1-2): p. 128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4732418</ArticleId><ArticleId IdType="pubmed">26399278</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P and Robberecht W, Recent advances in motor neuron disease. Curr Opin Neurol, 2009. 22(5): p. 486&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">19593125</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A, Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve, 1995. 18(7): p. 741&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783764</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, et al., The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler, 2010. 11(5): p. 439&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat RA, et al., Effect of reproductive factors and postmenopausal hormone use on the risk of amyotrophic lateral sclerosis. Neuroepidemiology, 2006. 27(3): p. 117&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">16946622</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al., Risk factors in motor neuron disease: a case-control study. Neuroepidemiology, 1991. 10(4): p. 174&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">1745327</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, et al., Extensive genetics of ALS: a population-based study in Italy. Neurology, 2012. 79(19): p. 1983&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484987</ArticleId><ArticleId IdType="pubmed">23100398</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al., Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol, 2016. 15(11): p. 1182&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Service, U.P.H., ALS registry act. 110th congress. Public Law , U.P.H. Service, Editor. 2008, US Public Health Service: Washington DC. p. 110&#x2013;373.</Citation></Reference><Reference><Citation>Brooks BR, El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J Neurol Sci, 1994. 124 Supp1: p. 96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">7807156</ArticleId></ArticleIdList></Reference><Reference><Citation>Antao VC and Horton DK, The National Amyotrophic Lateral Sclerosis (ALS) Registry. J Environ Health, 2012. 75(1): p. 28&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4549968</ArticleId><ArticleId IdType="pubmed">22866401</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen KD, et al., The National Registry of Veterans with amyotrophic lateral sclerosis. Neuroepidemiology, 2008. 30(3): p. 180&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">18421218</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al., The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci, 1999. 169(1-2): p. 13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton DK, Mehta P, and Antao VC, Quantifying a nonnotifiable disease in the United States: the National Amyotrophic Lateral Sclerosis Registry model. JAMA, 2014. 312(11): p. 1097&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550214</ArticleId><ArticleId IdType="pubmed">25057819</ArticleId></ArticleIdList></Reference><Reference><Citation>Services, U.D.o.H.a.H., US department of health and human services regions. , U.D.o.H.a.H. Services, Editor. 2017: Washington DC.</Citation></Reference><Reference><Citation>Bryan L, et al., Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data. PLoS One, 2016. 11(4): p. e0153683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4849726</ArticleId><ArticleId IdType="pubmed">27124833</ArticleId></ArticleIdList></Reference><Reference><Citation>Khishchenko N, et al., Time to diagnosis in the National Registry of Veterans with Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler, 2010. 11(1-2): p. 125&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">19153849</ArticleId></ArticleIdList></Reference><Reference><Citation>Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, 1995. 854: p. 1&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">8594834</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinic, M. Menopause. 1998.  [cited 2020 7/16/2020]; Available from: https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397.</Citation></Reference><Reference><Citation>Institute, S., SAS 9.4. Cary, NC.</Citation></Reference><Reference><Citation>Findlay JK, et al., Estrogen signaling in the regulation of female reproductive functions. Handb Exp Pharmacol, 2010(198): p. 29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4778970</ArticleId><ArticleId IdType="pubmed">20839084</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosano GM and Panina G, Oestrogens and the heart. Therapie, 1999. 54(3): p. 381&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10500455</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadkarni S, et al., Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes. Arterioscler Thromb Vasc Biol, 2011. 31(11): p. 2749&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3357483</ArticleId><ArticleId IdType="pubmed">21836070</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida M, et al., Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev, 2017. 97(1): p. 135&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5539371</ArticleId><ArticleId IdType="pubmed">27807202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarantino U, et al., Clinical guidelines for the prevention and treatment of osteoporosis: summary statements and recommendations from the Italian Society for Orthopaedics and Traumatology. J Orthop Traumatol, 2017. 18(Suppl 1): p. 3&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5688964</ArticleId><ArticleId IdType="pubmed">29058226</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarate S, Stevnsner T, and Gredilla R, Role of Estrogen and Other Sex Hormones in Brain Aging. Neuroprotection and DNA Repair. Front Aging Neurosci, 2017. 9: p. 430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5743731</ArticleId><ArticleId IdType="pubmed">29311911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, et al., Current and projected future economic burden of Parkinson's disease in the U.S. NPJ Parkinsons Dis, 2020. 6: p. 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7347582</ArticleId><ArticleId IdType="pubmed">32665974</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R and Singh M, Sex differences in cognitive impairment and Alzheimer's disease. Front Neuroendocrinol, 2014. 35(3): p. 385&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4087048</ArticleId><ArticleId IdType="pubmed">24434111</ArticleId></ArticleIdList></Reference><Reference><Citation>Villa A, et al., Estrogens, Neuroinflammation, and Neurodegeneration. Endocr Rev, 2016. 37(4): p. 372&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4971309</ArticleId><ArticleId IdType="pubmed">27196727</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, et al., Genetics and Sex in the Pathogenesis of Amyotrophic Lateral Sclerosis (ALS): Is There a Link? Int J Mol Sci, 2020. 21(10).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7279172</ArticleId><ArticleId IdType="pubmed">32455692</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong S, et al., Endogenous female reproductive hormones and the risk of amyotrophic lateral sclerosis. J Neurol, 2013. 260(2): p. 507&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">22972621</ArticleId></ArticleIdList></Reference><Reference><Citation>Grindler NM, et al., Persistent organic pollutants and early menopause in U.S. women. PLoS One, 2015. 10(1): p. e0116057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4309567</ArticleId><ArticleId IdType="pubmed">25629726</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Horton DK, and Mitsumoto H, Potential Environmental Factors in Amyotrophic Lateral Sclerosis. Neurol Clin, 2015. 33(4): p. 877&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4646848</ArticleId><ArticleId IdType="pubmed">26515627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjikoutis S and Wiles CM, Respiratory complications related to bulbar dysfunction in motor neuron disease. Acta Neurol Scand, 2001. 103(4): p. 207&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">11328190</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpont B, et al., Clinical features of pain in amyotrophic lateral sclerosis: A clinical challenge. Rev Neurol (Paris), 2019. 175(1-2): p. 11&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">30131172</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens HE, Joyce NC, and Oskarsson B, National Study of Muscle Cramps in ALS in the USA. Amyotroph Lateral Scler Frontotemporal Degener, 2017. 18(1-2): p. 32&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575819</ArticleId><ArticleId IdType="pubmed">27978764</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, et al., Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener, 2015. 16(3-4): p. 230&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye WE, et al., Evaluating the completeness of the national ALS registry, United States. Amyotroph Lateral Scler Frontotemporal Degener, 2018. 19(1-2): p. 112&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815913</ArticleId><ArticleId IdType="pubmed">29020837</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>